Literature DB >> 12235384

Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1.

Laurent Chaloin1, Maik Jörg Lehmann, Georg Sczakiel, Tobias Restle.   

Abstract

Aptamers, small oligonucleotides derived from an in vitro evolution process called SELEX, are promising therapeutic and diagnostic agents. Although very effective in vitro, only a few examples are available showing their potential in vivo. We have analyzed the effect of a well characterized pseudoknot RNA aptamer selected for tight binding to human immunodeficiency virus (HIV) type 1 reverse transcriptase on HIV replication. Transient intracellular expression of a chimeric RNA consisting of the human initiator tRNA(Met) (tRNA(Meti))/aptamer sequence in human 293T cells showed inhibition of HIV particle release by >75% when the cells were co-transfected with proviral HIV-1 DNA. Subsequent virus production of human T-lymphoid C8166 cells, infected with viral particles derived from co-transfected 293T cells, was again reduced by >75% as compared with the control. As the observed effects are additive, in this model for virus spread, the total reduction of HIV particle formation by transient intracellular expression of the pseudoknot RNA aptamer amounts to >95%. Low-dose HIV infection of human T cells stably expressing the aptamer did not show any virus replication over a period of 35 days. This is the first example of an RNA aptamer selected against a viral enzyme target to show powerful antiviral activity in HIV-1-permissive human T-lymphoid cell lines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235384      PMCID: PMC137107          DOI: 10.1093/nar/gkf522

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  48 in total

1.  RNA aptamers as effective protein antagonists in a multicellular organism.

Authors:  H Shi; B E Hoffman; J T Lis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

3.  Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.

Authors:  T Kuwabara; M Warashina; S Koseki; M Sano; J Ohkawa; K Nakayama; K Taira
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

Review 4.  Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery.

Authors:  W James
Journal:  Curr Opin Pharmacol       Date:  2001-10       Impact factor: 5.547

Review 5.  Intramers as promising new tools in functional proteomics.

Authors:  M Famulok; M Blind; G Mayer
Journal:  Chem Biol       Date:  2001-10

Review 6.  Strategies in the design of antiviral drugs.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2002-01       Impact factor: 84.694

7.  Controlling small guanine-nucleotide-exchange factor function through cytoplasmic RNA intramers.

Authors:  G Mayer; M Blind; W Nagel; T Böhm; T Knorr; C L Jackson; W Kolanus; M Famulok
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

8.  Generation of long read-through transcripts in vivo and in vitro by deletion of 3' termination and processing sequences in the human tRNAimet gene.

Authors:  S Adeniyi-Jones; P H Romeo; M Zasloff
Journal:  Nucleic Acids Res       Date:  1984-01-25       Impact factor: 16.971

9.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

10.  Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication.

Authors:  Timothy S Fisher; Pheroze Joshi; Vinayaka R Prasad
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

View more
  35 in total

1.  Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli.

Authors:  David G Nickens; James T Patterson; Donald H Burke
Journal:  RNA       Date:  2003-09       Impact factor: 4.942

2.  Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach.

Authors:  Xiaohong Fang; Weihong Tan
Journal:  Acc Chem Res       Date:  2010-01-19       Impact factor: 22.384

3.  Aptamers: problems, solutions and prospects.

Authors:  A V Lakhin; V Z Tarantul; L V Gening
Journal:  Acta Naturae       Date:  2013-10       Impact factor: 1.845

Review 4.  DNA-based therapeutics and DNA delivery systems: a comprehensive review.

Authors:  Siddhesh D Patil; David G Rhodes; Diane J Burgess
Journal:  AAPS J       Date:  2005-04-08       Impact factor: 4.009

Review 5.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

6.  RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production.

Authors:  Dhivya Ramalingam; Sonald Duclair; Siddhartha A K Datta; Andrew Ellington; Alan Rein; Vinayaka R Prasad
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

7.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

8.  SELEX-derived aptamers of the duck hepatitis B virus RNA encapsidation signal distinguish critical and non-critical residues for productive initiation of reverse transcription.

Authors:  Kanghong Hu; Jürgen Beck; Michael Nassal
Journal:  Nucleic Acids Res       Date:  2004-08-16       Impact factor: 16.971

Review 9.  Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.

Authors:  Jiehua Zhou; John J Rossi
Journal:  BioDrugs       Date:  2012-12-01       Impact factor: 5.807

10.  Novel bimodular DNA aptamers with guanosine quadruplexes inhibit phylogenetically diverse HIV-1 reverse transcriptases.

Authors:  Daniel Michalowski; Rebecca Chitima-Matsiga; Daniel M Held; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2008-11-07       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.